Products - Blood conditions | Topic | NICE

Guidance
Skip Standards and indicators submenu
Quality standards
Our quality standards set out priority areas for quality improvement. They highlight areas with identified variation in current practice.
View our quality standards
How to use our quality standards
The timeline for developing quality standards
Help us develop quality standards
Selecting and prioritising quality standards topics
About quality standards
Indicators
Our indicators measure outcomes that reflect the quality of care, or processes linked by evidence to improved outcomes.
View list of indicators
Learn about the committee that develops indicators
About indicators
Skip Life sciences submenu
Life Sciences
We offer tailored support to industry during product development. Our expertise can help you build the evidence needed to achieve market access.
View life sciences
Get support from NICE
NICE Advice service
Trusted, unrivalled expertise.
Make an enquiry
Contact us to discuss your requirements.
Innovative Licensing and Access Pathway (ILAP)
Streamlining patient access to safe, financially sustainable and innovative medicines.
Learn how we evaluate technologies
Health technology evaluation and topic selection manuals
Updated manuals for methods, processes and topic selection.
Digital health technologies
Accelerating our efforts to deliver innovation to the health and care system.
Evidence standards framework
Using the best available evidence to develop recommendations that guide decisions in health, public health and social care.
Our guidance programmes
Ensuring new technologies are clinically effective and offer economic value.
Register your product
Non-pharmaceutical
NHS Innovation Service is a clear and simple point of entry for health technologies to access support and national evaluation programmes.
Pharmaceutical
UK PharmaScan is a database of new medicines, indications and formulations in the pharmaceutical pipeline.
Find published and proposed evaluations
Diagnostics
Guidance on measurements and tests used to evaluate a patient's condition.
Medical technologies
Guidance on medical technologies put forward to NICE by manufacturers.
Technology appraisals
Guidance on new and existing medicines and treatments in the NHS.
Highly specialised technologies
Guidance on the use of highly specialised medicines and treatments.
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
Skip About submenu
About
NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.
Explore about
Our programmes
Learn about the information we produce.
Guidance
Advice
Quality standards
Indicators
Digital health
Topic selection
Get involved
Understand how decisions are made:
Attend a committee meeting
Comment on draft guidance:
Guidance in consultation
Be part of a guidance committee:
Join a committee
Help develop our products:
Register as a stakeholder
Putting you at the heart of our work:
Public involvement
What we do
Social care
Life sciences
NICE international
Patient safety
Shared decision making
Into practice
Social care quick guides
Measuring the use of NICE guidance
Resource planner
View all Into practice
Who we are
The board
The NICE strategy 2021 to 2026
Corporate publications
View all Who we are
- Contact us
- Jobs

Showing 61 products

Date | Title

Guidance programme: Technology appraisal guidanceRemove ‘Guidance programme: Technology appraisal guidance’ filter

Exagamglogene autotemcel for treating severe sickle cell disease in people 12 years and over (TA1044)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 February 2025
Vadadustat for treating symptomatic anaemia in adults having dialysis for chronic kidney disease (TA1035)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 January 2025
Andexanet alfa for reversing anticoagulation in people with intracranial haemorrhage (terminated appraisal) (TA1029)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 January 2025
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
15 January 2025
Published:
12 May 2021
Crovalimab for treating paroxysmal nocturnal haemoglobinuria in people 12 years and over (TA1019)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 November 2024
Danicopan with ravulizumab or eculizumab for treating paroxysmal nocturnal haemoglobinuria (TA1010)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 October 2024
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and over (TA1003)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
11 September 2024
Iptacopan for treating paroxysmal nocturnal haemoglobinuria (TA1000)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
4 September 2024
Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 July 2024
Momelotinib for treating myelofibrosis-related splenomegaly or symptoms (TA957)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
20 March 2024
Treosulfan with fludarabine before allogeneic stem cell transplant for people aged 1 month to 17 years with non-malignant diseases (terminated appraisal) (TA945)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
30 January 2024
Avatrombopag for treating primary chronic immune thrombocytopenia (TA853)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
15 December 2022
Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal) (TA846)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
29 November 2022
Luspatercept for treating anaemia caused by beta-thalassaemia (terminated appraisal) (TA843)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 November 2022
Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal) (TA844)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
24 November 2022
Fostamatinib for treating refractory chronic immune thrombocytopenia (TA835)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 October 2022
Roxadustat for treating symptomatic anaemia in chronic kidney disease (TA807)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
13 July 2022
Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria (TA778)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
9 March 2022
Ravulizumab for treating atypical haemolytic uraemic syndrome (TA710)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
23 June 2021
Ravulizumab for treating paroxysmal nocturnal haemoglobinuria (TA698)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
19 May 2021
Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura (TA667)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
16 December 2020
Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure (TA617)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
8 January 2020
Eltrombopag for treating chronic immune thrombocytopenia (TA293)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
26 October 2018
Published:
24 July 2013
Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
26 October 2018
Published:
27 April 2011
Eltrombopag for treating severe aplastic anaemia refractory to immunosuppressive therapy (terminated appraisal) (TA382)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
27 January 2016
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (TA323)
Product type:
Guidance
Programme:
Technology appraisal guidance
Published:
26 November 2014
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
26 March 2025
Marstacimab for treating severe haemophilia A or severe haemophilia B in people 12 years and over [ID6342]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
4 June 2025
Garadacimab for preventing recurrent attacks of hereditary angioedema in people 12 years and over [ID6394]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
21 August 2025
Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over [ID6284]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
17 December 2025
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly [ID1596]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Luspatercept for treating anaemia in non-transfusion dependent beta-thalassaemia [ID3870]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Canakinumab for untreated Schnitzler syndrome [ID4063]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Concizumab for preventing bleeding episodes in haemophilia A or haemophilia B [ID5099]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Emicizumab for preventing bleeding episodes in people with mild or moderate haemophilia A [ID5098]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
ABP 959 (eculizumab biosimilar) for treating paroxysmal nocturnal haemoglobinuria [TSID10250]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Apadamtase alfa for preventing and treating congenital thrombotic thrombocytopenic purpura caused by ADAMTS-13 deficiency [ID6192]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Crizanlizumab for preventing recurrent vaso-occlusive crises in sickle cell disease in young people aged 12 to 17 [TSID10766]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ravulizumab for untreated thrombotic microangiopathy after a haematopoietic stem cell transplant in people aged 28 days and over [TSID10642]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Subcutaneous ravulizumab for treating paroxysmal nocturnal haemoglobinuria or atypical haemolytic uraemic syndrome [TSID11820]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Giroctocogene fitelparvovec for treating moderately severe to severe haemophilia A ID6312
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Subcutaneous C1-esterase inhibitor for preventing recurrent attacks of hereditary angioedema in people 12 years and over [TSID11891]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Rilzabrutinib for treating persistent or chronic immune thrombocytopenia in people aged 12 and over [ID6395]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia [TSID11977]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over [ID6400]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Donidalorsen for preventing hereditary angioedema attacks in people 12 years and over [ID6457]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Ferric maltol for treating iron deficiency anaemia in children and adolescents aged 1 month to 17 years TS ID 11994
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Budesonide oral suspension for maintaining remission of eosinophilic oesophagitis in people 2 years and over [ID6486]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Avatrombopag for treating primary chronic immune thrombocytopenia in people 1 to 17 years [TSID12109]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Olezarsen for treating familial chylomicronaemia syndrome [TSID11993]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Berotralstat for preventing recurrent attacks of hereditary angioedema in children aged 2 to 12 years [TSID 12132]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Inclacumab for preventing recurrent vaso-occlusive crises in sickle cell disease in people 16 years and over [TSID12144]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Marstacimab for treating severe haemophilia A or B in people 12 years and over with inhibitors to factor-replacement therapy [TSID12143]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Veverimer for treating metabolic acidosis in chronic kidney disease [ID3832]
Status:
Topic selection
Programme:
Technology appraisal guidance
Expected publication date:
TBC